rs17851657

Variant summary

Our verdict is Benign. Variant got -8 ACMG points: 0P and 8B. BA1

This summary comes from the ClinGen Evidence Repository: The filtering allele frequency of the c.453C>T (p.Asp151=) variant in the MAP2K2 gene is 27.128% (10569/38338) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581) LINK:https://erepo.genome.network/evrepo/ui/classification/CA137943/MONDO:0021060/004

Frequency

Genomes: 𝑓 0.14 ( 1972 hom., cov: 33)
Exomes 𝑓: 0.19 ( 27044 hom. )

Consequence

MAP2K2
NM_030662.4 splice_region, synonymous

Scores

2

Clinical Significance

Benign reviewed by expert panel B:12O:1

Conservation

PhyloP100: -0.278
Variant links:
Genes affected
MAP2K2 (HGNC:6842): (mitogen-activated protein kinase kinase 2) The protein encoded by this gene is a dual specificity protein kinase that belongs to the MAP kinase kinase family. This kinase is known to play a critical role in mitogen growth factor signal transduction. It phosphorylates and thus activates MAPK1/ERK2 and MAPK2/ERK3. The activation of this kinase itself is dependent on the Ser/Thr phosphorylation by MAP kinase kinase kinases. Mutations in this gene cause cardiofaciocutaneous syndrome (CFC syndrome), a disease characterized by heart defects, cognitive disability, and distinctive facial features similar to those found in Noonan syndrome. The inhibition or degradation of this kinase is also found to be involved in the pathogenesis of Yersinia and anthrax. A pseudogene, which is located on chromosome 7, has been identified for this gene. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -8 ACMG points.

BA1
For more information check the summary or visit ClinGen Evidence Repository.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
MAP2K2NM_030662.4 linkuse as main transcriptc.453C>T p.Asp151= splice_region_variant, synonymous_variant 4/11 ENST00000262948.10 NP_109587.1
MAP2K2XM_006722799.3 linkuse as main transcriptc.453C>T p.Asp151= splice_region_variant, synonymous_variant 4/9 XP_006722862.1
MAP2K2XM_047439100.1 linkuse as main transcriptc.-118C>T splice_region_variant, 5_prime_UTR_variant 2/9 XP_047295056.1

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
MAP2K2ENST00000262948.10 linkuse as main transcriptc.453C>T p.Asp151= splice_region_variant, synonymous_variant 4/111 NM_030662.4 ENSP00000262948 P1

Frequencies

GnomAD3 genomes
AF:
0.141
AC:
21512
AN:
152112
Hom.:
1967
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.0441
Gnomad AMI
AF:
0.195
Gnomad AMR
AF:
0.128
Gnomad ASJ
AF:
0.230
Gnomad EAS
AF:
0.0430
Gnomad SAS
AF:
0.200
Gnomad FIN
AF:
0.176
Gnomad MID
AF:
0.209
Gnomad NFE
AF:
0.196
Gnomad OTH
AF:
0.154
GnomAD3 exomes
AF:
0.163
AC:
36340
AN:
222968
Hom.:
3477
AF XY:
0.170
AC XY:
20555
AN XY:
120626
show subpopulations
Gnomad AFR exome
AF:
0.0416
Gnomad AMR exome
AF:
0.0893
Gnomad ASJ exome
AF:
0.215
Gnomad EAS exome
AF:
0.0350
Gnomad SAS exome
AF:
0.213
Gnomad FIN exome
AF:
0.175
Gnomad NFE exome
AF:
0.203
Gnomad OTH exome
AF:
0.179
GnomAD4 exome
AF:
0.188
AC:
271555
AN:
1443232
Hom.:
27044
Cov.:
31
AF XY:
0.189
AC XY:
135803
AN XY:
716686
show subpopulations
Gnomad4 AFR exome
AF:
0.0397
Gnomad4 AMR exome
AF:
0.0933
Gnomad4 ASJ exome
AF:
0.220
Gnomad4 EAS exome
AF:
0.0531
Gnomad4 SAS exome
AF:
0.208
Gnomad4 FIN exome
AF:
0.186
Gnomad4 NFE exome
AF:
0.200
Gnomad4 OTH exome
AF:
0.175
GnomAD4 genome
AF:
0.141
AC:
21533
AN:
152230
Hom.:
1972
Cov.:
33
AF XY:
0.140
AC XY:
10386
AN XY:
74422
show subpopulations
Gnomad4 AFR
AF:
0.0441
Gnomad4 AMR
AF:
0.128
Gnomad4 ASJ
AF:
0.230
Gnomad4 EAS
AF:
0.0431
Gnomad4 SAS
AF:
0.202
Gnomad4 FIN
AF:
0.176
Gnomad4 NFE
AF:
0.196
Gnomad4 OTH
AF:
0.160
Alfa
AF:
0.178
Hom.:
1281
Bravo
AF:
0.132
Asia WGS
AF:
0.143
AC:
501
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Benign:12Other:1
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

not specified Benign:5
Benign, criteria provided, single submitterclinical testingPreventionGenetics, part of Exact Sciences-- -
Benign, criteria provided, single submitterclinical testingLaboratory for Molecular Medicine, Mass General Brigham Personalized MedicineJul 29, 2008- -
Benign, no assertion criteria providedclinical testingClinical Genetics, Academic Medical Center-- -
Benign, criteria provided, single submitterclinical testingGeneDxJan 24, 2012This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -
Benign, no assertion criteria providedclinical testingDiagnostic Laboratory, Department of Genetics, University Medical Center Groningen-- -
RASopathy Benign:3
Benign, no assertion criteria providedclinical testingBaylor Genetics-Variant classified using ACMG guidelines -
Benign, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpFeb 01, 2024- -
Benign, reviewed by expert panelcurationClinGen RASopathy Variant Curation Expert PanelMay 09, 2017The filtering allele frequency of the c.453C>T (p.Asp151=) variant in the MAP2K2 gene is 27.128% (10569/38338) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581) -
Cardiofaciocutaneous syndrome 4 Benign:2
Benign, criteria provided, single submitterclinical testingGenome-Nilou LabSep 05, 2021- -
Benign, criteria provided, single submitterclinical testingARUP Laboratories, Molecular Genetics and Genomics, ARUP LaboratoriesNov 29, 2023- -
not provided Benign:1Other:1
not provided, no classification providedphenotyping onlyGenomeConnect, ClinGen-GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant. -
Benign, criteria provided, single submitternot providedBreakthrough Genomics, Breakthrough Genomics-- -
Cardiovascular phenotype Benign:1
Benign, criteria provided, single submitterclinical testingAmbry GeneticsJan 21, 2019This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.72
CADD
Benign
0.24
DANN
Benign
0.77
RBP_binding_hub_radar
0.97
RBP_regulation_power_radar
2.9

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs17851657; hg19: chr19-4102449; COSMIC: COSV53562460; COSMIC: COSV53562460; API